From Brain to Battlefield: MSX's Pre-IPO Bet on the Two Extremes of AI

Tracing the code back to its chaotic genesis, one finds that the most audacious investment theses are rarely about technology at all. They are about narratives. And the latest narrative to emerge from the Pre-IPO shadows is a doozy: MSX, a fund that typically deals in quiet, backroom allocations, has reportedly brought both Neuralink and Anduril into its third Pre-IPO tranche. On the surface, this is a portfolio construction move. Dig deeper, and it is a philosophical statement about where the industry believes the next decade of value creation will actually occur. It is a bet on the two most extreme, most ethically fraught, and most potentially lucrative frontiers of artificial intelligence: the human mind and the autonomous battlefield. The announcement, which has been circulating through private market channels, is light on specifics. No valuation figures were officially confirmed, no equity stakes disclosed. But the signal is loud. MSX is not just buying into AI hype; it is buying into the physical and biological manifestation of AI. This is a far cry from the SaaS and infrastructure plays that dominated the last cycle. This is a bet on wetware and warfare, on electrodes and autonomous drones. The question is whether this is a prescient allocation or a narrative-driven trap. Let's start with the context, because the two companies could not be more different in their operational realities. Neuralink, Elon Musk's brain-computer interface venture, is still in its clinical infancy. As of late 2025, the company has implanted its N1 chip in just three human patients. The technology is undeniably impressive—a 1,024-channel flexible electrode array, inserted by a surgical robot designed to avoid vascular damage. The FDA has granted it breakthrough device designation, and a new feasibility study, dubbed CONVOY, aims to connect the implant to a robotic arm for paralyzed patients. But this is a company with essentially zero revenue, a long regulatory runway, and a technology that requires drilling into a human skull. Its valuation, estimated between $8 and $10 billion in recent private rounds, is based entirely on future potential, not present performance. Anduril, on the other hand, is a revenue-generating machine. The defense tech company, founded by Palmer Luckey, has pivoted from a scrappy startup to a serious contender in the military-industrial complex. Its Lattice software platform, which fuses sensor data and enables autonomous decision-making, is the core of its "software-defined defense" thesis. In 2025, the company is projected to pull in around $1 billion in revenue, a 150% year-over-year increase. It has contracts with the US Department of Defense, the UK Ministry of Defence, and a strategic partnership with OpenAI to develop counter-drone systems. Its valuation, which sat at $14 billion in 2024, is rumored to be heading toward $25-30 billion in its next raise. This is a company that has moved from proof-of-concept to production scale, with a product suite that includes autonomous submarines, loitering munitions, and a 3D-printed drone manufacturing capability acquired for over $1.3 billion. So, what is the core insight here? It is not that MSX is diversifying. It is that MSX is betting on the convergence of AI with the physical world, and more specifically, on the two most extreme endpoints of that convergence. Neuralink represents the augmentation of the human operator. Anduril represents the replacement of the human operator. One is about enhancing the biological, the other about making it obsolete. This is the full spectrum of AI's potential impact, and MSX is positioning itself to capture value at both poles. Based on my experience auditing governance proposals and dissecting market narratives, this is a classic "barbell strategy" applied to deep tech. You hold the high-risk, high-reward speculative asset (Neuralink) alongside the more established, cash-flowing asset (Anduril) to balance the portfolio's risk profile. But here is where the logic meets the absurdity of market hype. The valuations in play are staggering, and they are predicated on a series of assumptions that are far from guaranteed. For Neuralink, the bull case requires a flawless execution of FDA approvals, a scale-up from 3 patients to thousands, and a resolution of the profound ethical and safety questions surrounding invasive brain implants. The bear case is equally clear: a single serious adverse event—an infection, a device failure, a signal degradation issue—could set the company back years and decimate its valuation. The technology is promising, but the path to commercialization is littered with regulatory landmines and biological unknowns. The electrode array, which is thinner than a human hair, must survive for decades in the corrosive environment of the human body. That is a materials science problem that has not yet been solved. Anduril, while more mature, faces a different set of risks. Its revenue is heavily concentrated in a single customer: the US Department of Defense. A shift in political priorities, a budget cut, or a geopolitical de-escalation could severely impact its growth trajectory. Furthermore, the "software-defined defense" model is facing increasing competition from traditional prime contractors like Lockheed Martin and RTX, who are rapidly building their own AI capabilities. Anduril's edge is its agility and its software-first approach, but the incumbents have decades of relationships, manufacturing scale, and political capital. The question is not whether Anduril can win contracts; it is whether it can sustain its growth rate as the competition catches up. The $2.5 billion "large-scale expeditionary warfare" contract from the Defense Innovation Unit is a significant win, but it is a drop in the bucket compared to the budgets of the traditional primes. The contrarian angle here is that the "AI narrative" premium may be masking fundamental valuation risks. In the silence between the block hashes, we must ask: are we pricing in the technology, or are we pricing in the story? Neuralink's valuation implies a future where brain-computer interfaces are as common as smartphones. That is a future that may be 20 years away, if it arrives at all. Anduril's valuation implies a future of persistent, autonomous warfare, a future that is ethically fraught and politically volatile. The market is currently rewarding these narratives, but narratives are fragile. They can be punctured by a single disappointing clinical trial, a single failed mission, or a single change in the political winds. Logic fails, but the narrative persists. That is the nature of the Pre-IPO market. It is a market built on belief, on the conviction that the future will look a certain way. MSX is betting that the future is one where AI is not just a tool we use, but a system we inhabit and a force we deploy. It is a bold, some might say reckless, thesis. But it is also a coherent one. By holding both Neuralink and Anduril, MSX is hedging its bets on the two most likely paths to AI's physical manifestation. If the human-machine interface becomes the next computing platform, Neuralink is a winner. If autonomous systems become the new arsenal of democracy, Anduril is a winner. The fund is betting on the inevitability of both. An evangelist who doubts his own gospel might point out the uncomfortable truth: this is a bet on the failure of human governance. It is a bet that we will not be able to regulate brain-computer interfaces effectively, and that we will not be able to prevent the proliferation of autonomous weapons. It is a bet that the most profound technological advancements of our time will be driven by the private sector, with all its incentives and biases, rather than by public institutions. This is not a criticism of MSX; it is a criticism of the system that makes such bets necessary. The fund is simply playing the game as it is structured. The question is whether the game itself is sustainable. So, what is the takeaway? This is not a story about two companies. It is a story about the direction of capital and the direction of our species. The fact that a Pre-IPO fund is willing to allocate significant resources to both a brain implant company and a defense AI company tells us that the market believes the future is one of radical human enhancement and radical automation of conflict. Whether that future is desirable is a question for philosophers and policymakers. Whether it is profitable is a question for MSX. But for the rest of us, this is a signal. The frontier of AI is no longer in the cloud. It is in our heads and on our battlefields. The code is being written, and it is being written in blood and neurons. The only question that remains is whether we are writing a story of liberation or a story of subjugation. The market has made its bet. The rest of us are just living in it.